Compare Blue Owl Capital Inc. Class A Common Stock (OWL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blue Owl Capital Inc. Class A Common Stock vs Summit Therapeutics Inc — how do they compare? Blue Owl Capital Inc. Class A Common Stock trades at $8.8 (market cap $6.01B), while Summit Therapeutics Inc trades at $15 (market cap $12.07B). The key difference: Summit Therapeutics Inc is far larger — about 2× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 10.35% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Blue Owl Capital Inc. Class A Common Stock for 0 Days and Summit Therapeutics Inc for 16 Days on average.
| OWL | SMMT | |
|---|---|---|
Market Cap | $6.01B | $12.07B |
Volume | 24,327,195 | 4,658,232 |
Sector | Financials | Health |
52-Week High | $17.17 | $26.38 |
52-Week Low | $8.23 | $12.43 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $10.19B | $11.40B |
Dividend Yield | 10.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today despite recent positive catalysts including a $2 billion strategic investment from AstraZeneca announced September 28, 2026. The stock shows bullish technical signals with strong institutional support, though fundamentals reflect a pre-revenue biotech with significant losses (-$1.08B net income in 2025) and negative ROE of -192.5%. Recent clinical trial collaborations with major pharma partners highlight the company's promising ivonescimab cancer drug pipeline.
The outlook balances substantial upside potential from AstraZeneca's validation and clinical progress against high execution risks typical of developmental biotechs. With 65% analyst buy ratings and a $29.33 consensus target suggesting 89% upside, the stock offers high-risk/high-reward exposure to innovative cancer therapeutics, dependent on successful drug development and regulatory approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
